NCT06315257招募中1 期
A Randomized, Open-label Clinical Trial to Assess the Safety, Feasibility and Immunogenicity of Adjuvant PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins4 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2025年7月23日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 32
- 试验地点
- 4
- 主要终点
- Safety of PVX7 as assessed by adverse events
研究概览
简要总结
A Feasibility Trial of PVX7 vaccine in advanced cervical cancer patients who have completed primary definitive therapy.
详细描述
A Feasibility Trial of PVX7 in advanced cervical cancer patients who have completed primary definitive therapy.
- Safety and immunogenicity study
- Patients are randomized in a 1:1 ratio to two cohorts, up to 16 patients in each of intramuscular or skin inoculation vaccine injection, up to 32 patients total
- Human Immunodeficiency Virus (HIV)-negative patients only
- Treatment dose: Arm A: pBI-11 DNA (3 mg) twice via intramuscular (IM) injection, followed by one dose of TA-HPV (2.5x10^5 pfu) via skin inoculation; Arm B: pBI-11 DNA (3 mg) twice, followed by one dose of TA-HPV (10^7 pfu) via IM injection
- Schedule for administration: PVX7 vaccination at weeks 1, 5, and 9
- Follow-up for 2 years per standard of care (SoC)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female subjects age 18 years or older with diagnosis of advanced (stage IB1-IVA) HPV+ cervical cancer and have completed primary treatment (consisting of any of the following as per NCCN guideline standard of care: surgical resection, radiation, and/or platinum-based chemotherapy) within the past 12 months.
- •Patients who are recommended to receive anto-PD-1 or anti-PD-L1 therapy after chemoradiation are eligible to enroll and can continue to receive such therapy while receiving study drug.
- •No history of or current evidence of residual disease or disease recurrence based on imaging and clinical assessments within 8 weeks of enrollment
- •HIV uninfected
- •Hepatitis B surface antigen negative
- •Anti-hepatitis C (HCV) antibody negative or negative HCV polymerase chain reaction (PCR)
- •Patients who are able and willing to comply with all study procedures and voluntarily sign an informed consent form
- •Adequate organ function as defined by the following parameters:
- •white blood cell count ≥ 3,000 cells/cu mm
- •lymphocyte number ≥ 500 cells/cu mm
- •absolute neutrophil count ≥ 1,000 cells/cu mm
- •platelets ≥ 90,000/cu mm
- •hemoglobin ≥ 9 g/dL
- •total bilirubin <1.5 X upper limit of normal (ULN), <3 x ULN if Gilbert's disease
- •Aspartate Transferase(AST) and Alanine Transaminase (ALT) <3 X ULN
- •creatinine < 1.5 X ULN or estimated creatinine clearance ≥ 60 ml/min per Modified Cockcroft-Gault Formula
- •Eastern Cooperative Oncology Group performance status of 0 or 1
- •All clinically significant toxicities related to prior therapy should be less than or equal to Grade 1 at time of enrollment
- •Ability and willingness for one month post vaccination to follow vaccine inoculation site care and avoid close social contact with children under 1 year old or close social or domestic contact with a pregnant woman or individuals at high risk of serious adverse effects of vaccinia virus, for instance, those with past or present eczema, or immunodeficiency states including HIV infection
排除标准
- •Women of child-bearing potential (i.e., those who have had fertility-sparing procedures for the management of cervical cancer) will be excluded unless agreed to remain sexually abstinent or have a partner who is sterile (i.e. vasectomy), or use methods of contraception (e.g., oral contraception, barrier methods, spermicide, intrauterine device (IUD)), throughout the first 6 months of the study.
- •Because there is a risk for adverse events in nursing infants, breastfeeding must be discontinued if the mother is treated on study.
- •Diagnosed with a recognized immunodeficiency disease including cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia; patients diagnosed with acquired, hereditary, or congenital immunodeficiencies
- •Diagnosis with a medical condition that requires systemic treatment with immunosuppressive drugs such as cyclosporine, adrenocorticotropic hormone (ACTH), alkylating agents, antimetabolites, radiation, Tumor Necrosis Factor (TNF) inhibitors, or systemic corticosteroids, either chronically or within 30 days of first PVX7 vaccination.
- •Administration of any blood product within 30 days of signing informed consent.
- •Need for ongoing therapeutic anticoagulation during the study period due to concern for increased risk of bleeding.
- •Previous severe allergic reaction or hypersensitivity to a vaccine or any of its components
- •Participation in a study with an investigational compound or device within 30 days of signing informed consent
- •Known active central nervous system disease
- •Surgery within 30 days of first PVX7 vaccination, excluding minor procedures
- •Diagnosis with an uncontrolled intercurrent illness including, but not limited to, ongoing, or active infection, or psychiatric illness/social situations that would limit compliance with study requirements
- •Diagnosis with an active autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus (SLE), ulcerative colitis, Crohn's Disease, multiple sclerosis (MS), ankylosing spondylitis)
- •History of myocarditis or pericarditis.
- •Known underlying heart disease (e.g., cardiomyopathy, congestive heart failure, symptomatic arrhythmia not controlled by medication, unstable angina, history of acute myocardial infarction or cerebrovascular accident within the past 6 months).
- •Patients and the patients close social, sexual, or domestic contacts may not have non-healed wounds or active exfoliative skin conditions such as: Eczema, Burns, Impetigo, Varicella-zoster virus infection, Herpes simplex virus infection, Severe acne, Severe diaper dermatitis with extensive areas of denuded skin, Psoriasis, Lichen planus, Darier disease (keratosis follicularis).
- •History or presence of atopic dermatitis
- •Inability or unwillingness to for one month post vaccination follow vaccine inoculation site care and avoid social contact with children under 1 year old or close social or domestic contact with a pregnant woman or individuals at high risk of serious adverse effects of vaccinia virus, for instance, those with past or present eczema, or immunodeficiency states including HIV infection
研究组 & 干预措施
pBI-11 DNA plus TA-HPV via IM Injection
Experimental
Participants will receive pBI-11 DNA and TA-HPV via IM Injection
干预措施: PVX7 (Drug)
pBI-11 DNA plus TA-HPV via Skin Inoculation
Experimental
Participants will receive pBI-11 DNA by IM injection and TA-HPV via Skin Inoculation
干预措施: PVX7 (Drug)
结局指标
主要结局
Safety of PVX7 as assessed by adverse events
时间窗: 12 months
To assess the safety of PVX7 immunotherapy to patients with advanced cervical cancer who have completed primary therapy by evaluating Adverse Events (AEs).
Feasibility of PVX7
时间窗: 12 months
To assess the feasibility of PVX7 immunotherapy to patients with advanced cervical cancer who have completed primary therapy. Feasibility is measured by the ability of patients to receive all three doses of vaccine.
次要结局
- Immune Response(12 months)
- Presence of circulating HPV DNA(12 months)
- Cellular Immune Response(12 months)
研究者
研究点 (4)
Loading locations...
相似试验
终止
1 期
A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047Adenoviral InfectionNCT03160339Emergent BioSolutions25
已完成
1 期
Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy SubjectsIn Development for Cystic FibrosisNCT01208285Vertex Pharmaceuticals Incorporated24
Unknown
2 期
A Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical CancerDisease Free SurvivalNCT04138992Air Force Military Medical University, China150
尚未招募
1 期
HYpofractionated Pelvic Radiotherapy for Advanced Cervical Cancers INeligible for ChemoTherapyLocally Advanced Cervical CarcinomaNCT05210270University of Santo Tomas Hospital, Philippines55
进行中（未招募）
3 期
Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN GuidelineUterine Cervical NeoplasmsCervical CancerNCT04723875Huazhong University of Science and Technology306